MS Speaks

When Tysabri was the newest MS drug, it wasn't long before we began hearing of cases of progressive multifocal leukoencephalopathy (PML). But we kept hearing that these were very very rare, and not to be too concerned. However, other MS drugs came along, and some of them led to some other cases of PML. And some people with PML died.


But not to worry. PML is so very rare. However, the medical profession is concerned about it, as is evident in this abstract.


From PubMed (July 25, 2023)--"Progressive multifocal leukoencephalopathy:  Pathogenesis, diagnostic tools, and potential biomarkers of response to therapy":


https://pubmed.ncbi.nlm.nih.gov/37487750/


From the abstract:

In the last two decades, there has been increasing concern among patients and the medical community as PML was observed as an adverse event in individuals treated with modern (selective) immune suppressive treatments for various immune-mediated diseases, especially multiple sclerosis (MS). It became evident that this devastating complication also needs to be considered beyond the patient populations historically at risk, including those with hematological malignancies or HIV-infected individuals.